
Commentary / Japan Nov 18, 2020
Can Japan bridge the vaccine divide?
Japan too has been developing its own drug, Avigan, against COVID-19. Yet the drug being developed by Fujifilm is not a vaccine but rather a treatment for coronavirus symptoms.
For Shihoko Goto's latest contributions to The Japan Times, see below:
Japan too has been developing its own drug, Avigan, against COVID-19. Yet the drug being developed by Fujifilm is not a vaccine but rather a treatment for coronavirus symptoms.
The pandemic has made clear that the world is actually now much more borderless than it has ever been.
For Japan’s ambitious female politicians, the German chancellor's approach to climbing up the political ladder by not focusing on gender issues is instructive.
For the nation to be an inspiration, it must make better use of the momentum of the new ways of doing business that the pandemic has brought about across the globe.
Xenophobia must be treated as a grave risk that is as contagious and as deadly as any virus.
The pandemic presents a golden opportunity for Japan to think outside the box and re-evaluate how to innovate to meet its changing needs.
Despite Japan's ability to keep COVID-19's spread in check, few countries have looked to the Abe administration as an example to follow.
This is the month when students find out whether months or even years of exam preparation have finally paid off or not.
Looking ahead, what Japan needs is to capitalize on that stability and take risks to address the very real longer-term challenges.
Japan could represent an alternative path for growth and defining economic success.